Subscribe: Nature Reviews Cancer - Issue - nature.com science feeds
http://www.nature.com/nrc/current_issue/rss
Added By: Feedage Forager Feedage Grade B rated
Language: English
Tags:
cancer nanomedicine  cancer  cancers  carcinoma  cell  cells  clonal  leukaemia  long term  nature  relapse  reviews cancer  tumour  tumours 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Nature Reviews Cancer - Issue - nature.com science feeds

Nature Reviews Cancer - Issue - nature.com science feeds





 



Immunotherapy: Switching off immune suppression

2016-12-09

Two papers have shown in mouse tumour models that targeting PI3Kγ in myeloid cells can reduce immune suppression and increase the efficacy of immune checkpoint inhibitors.



Cell migration: Caged for protection

2016-12-02

Skau et al. demonstrate that the actin nucleating protein FMN2 generates a perinuclear actin and focal adhesion-based structure to protect the nucleus from damage during cell migration through confining 3D microenvironments.



Lymphoma: Now you see it...

2016-12-16

Scherer et al. show that analysis of circulating tumour DNA can provide prognostic information and predict relapse in patients with diffuse large B-cell lymphoma.



Tumour-Initiating cells: The cell that rocks the tumour

2016-12-21

Latil et al. have shown that the cell of origin of squamous cell carcinomas (SCCs) controls epithelial-to-mesenchymal transition (EMT) and aggressiveness of these tumours. SCCs derived from hair follicles are much more prone to undergo EMT and have more metastatic potential compared with SCCs



Leukaemia: Don't let sleeping cells lie

2016-12-21

In many patients with acute lymphoblastic leukaemia (ALL), most cells respond to chemotherapy but a minority show resistance and cause relapse with poor outcome. Using patient-derived xenograft models, Ebinger et al. identified a subpopulation of resistant and relapse-inducing cells with long-term dormancy and stemness



Chemotherapy: Less is more

2016-12-21

In response to maximum tolerated doses of chemotherapy, Chan et al. found that cancer-associated fibroblasts are activated through increased activity of signal transducer and activator of transcription 1 (STAT1) and nuclear factor-κB (NF-κB), leading to elevated levels and release of ELR+ chemokines.



Cancer genetics: X-inactivation and cancer incidence

2016-12-21

Males have a higher risk than females of developing many cancers but the reasons for this disparity are unclear. Dunford et al. analysed exome sequences of 4,126 tumours across 21 cancer types and identified some tumour suppressor genes on the X chromosome that escape



The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia

2016-11-11

Myelodysplastic syndrome (MDS) is a clonal disease that arises from the expansion of mutated haematopoietic stem cells. In a spectrum of myeloid disorders ranging from clonal haematopoiesis of indeterminate potential (CHIP) to secondary acute myeloid leukaemia (sAML), MDS is distinguished by the presence of peripheral



Cancer nanomedicine: progress, challenges and opportunities

2016-11-11

The intrinsic limits of conventional cancer therapies prompted the development and application of various nanotechnologies for more effective and safer cancer treatment, herein referred to as cancer nanomedicine. Considerable technological success has been achieved in this field, but the main obstacles to nanomedicine becoming a



TIMPs: versatile extracellular regulators in cancer

2016-12-09

A compelling long-term goal of cancer biology is to understand the crucial players during tumorigenesis in order to develop new interventions. Here, we review how the four non-redundant tissue inhibitors of metalloproteinases (TIMPs) regulate the pericellular proteolysis of a vast range of matrix and cell



Deciphering the divergent roles of progestogens in breast cancer

2016-11-25

Most breast cancers are driven by oestrogen receptor-α. Anti-oestrogenic drugs are the standard treatment for these breast cancers; however, treatment resistance is common, necessitating new therapeutic strategies. Recent preclinical and historical clinical studies support the use of progestogens to activate the progesterone receptor (PR) in



The disparate origins of ovarian cancers: pathogenesis and prevention strategies

2016-11-25

Ovarian cancer is the fifth cause of cancer-related death in women and comprises a histologically and genetically broad range of tumours, including those of epithelial, sex cord-stromal and germ cell origin. Recent evidence indicates that high-grade serous ovarian carcinoma, clear cell carcinoma and endometrioid carcinoma



Gap junctions and cancer: communicating for 50 years

2016-12-02

Nature Reviews Cancer16, 775–78810.1038/nrc.2016.105(2016)On page 779 of the above article there were errors in line 7 of Table 1. The carcinogen used in the mouse model was DEN and the outcome was increased liver tumours in



That gut feeling

2016-12-16

Tumour microenvironment